Adaptive Biotechnologies Corporation (NASDAQ: ADPT) saw its shares decline 9.2% in after-hours trading on Monday after the company unveiled plans to issue $250 million of convertible senior notes due in 2031.
The planned offering is structured as a private placement to qualified institutional buyers. Initial purchasers in the transaction will have an option to acquire up to an additional $37.5 million of notes within 13 days of the issuance.
Adaptive Biotechnologies disclosed several intended uses for the capital raised. A portion of the proceeds is slated to repay the OrbiMed Purchase Agreement. The company also intends to enter into capped call transactions that carry a premium of at least 75% and to repurchase up to $25 million of its common stock as a means of mitigating potential dilution tied to the convertible notes. Any remaining proceeds are earmarked for general corporate purposes and for opportunistic initiatives within the company’s Minimal Residual Disease (MRD) business.
Details on the securities show the notes will be senior, unsecured obligations that accrue interest payable on a semi-annual basis and mature on July 1, 2031. Noteholders will be entitled to convert their notes under certain circumstances, with conversions to be settled by the company in cash, shares of common stock, or a combination of both.
The company retains the right to redeem the notes beginning July 1, 2029, subject to conditions. Redemption can occur if the company’s stock trades above 130% of the conversion price for a specified period and other criteria are satisfied.
Separately, Adaptive Biotechnologies said it will pursue a formal separation of its MRD and Immune Medicine businesses. Management is assessing strategic and structural alternatives for the Immune Medicine unit and expects to identify its preferred separation path by year-end 2026.
The combination of the debt offering, capped calls, and share repurchase plan is presented as a package intended to both provide capital and limit dilution from potential conversions. The announcement and the financing mechanics appeared to be the proximate cause for the after-hours share decline reported Monday.
Clear summary
Adaptive Biotechnologies announced a private placement of $250 million in convertible senior notes due 2031, with an initial purchaser option for an additional $37.5 million. Proceeds will partly repay an OrbiMed Purchase Agreement, fund capped calls and a potential $25 million stock buyback to limit dilution, and support corporate and MRD initiatives. The company also plans to pursue a separation of its MRD and Immune Medicine businesses, intending to select a preferred path by year-end 2026.